KineMed President and Scientific Founder Marc Hellerstein to Present the Role of Blood-Based Biomarkers in Muscle Wasting Disease at the 7th Cachexia Conference in Kobe, Japan

EMERYVILLE, Calif.

KineMed, Inc. (www.kinemed.com) announced today that Marc Hellerstein, M.D., Ph.D., President, CSO, and Scientific Founder of KineMed, will present at the 7th Cachexia Conference in a session titled “Developing therapies for cachexia & sarcopenia.” Dr. Hellerstein’s presentation will take place Wednesday, December 11th from 1:30-3:00 PM JST, in Kobe, Japan.

The need for minimally invasive tests that reveal the mass and intracellular protein metabolism of skeletal muscle in humans has been recognized for decades. The absence of biomarkers for muscle biology has limited the development of both drug and nutritional therapies for muscle wasting diseases like cachexia and sarcopenia. Dr. Hellerstein will describe recent methodologic advances that have led to three new biomarker tests of muscle biology: muscle mass from a spot urine sample; turnover of the global proteome from muscle tissue; and muscle protein synthesis rates from a plasma sample.

“There are many compelling examples where informative biomarkers have changed therapeutics and management of diseases, and the absence of biomarkers for muscle biology has limited the development of both drug and nutritional therapies for cachexia and sarcopenia,” said Dr. Hellerstein. “I will discuss recent striking advances in biomarker tests for key aspects of in vivo muscle biology in humans, based on important methodological developments. These biomarker tests have potentially valuable applications in both prescription and non-prescription therapeutics, as well as for drug development in sarcopenia, cachexia and muscular dystrophies.”

The advances Dr. Hellerstein will describe are components of KineMed’s proprietary biomarker platform technology and include:

• The Company’s proprietary test of muscle mass from a spot urine sample;
• A proprietary Proteome Dynamics technique, which can measure the turnover of the global muscle proteome from muscle biopsy tissue;
• A proprietary “virtual kinetic biopsy” approach, wherein the synthesis and breakdown rates of skeletal muscle proteins can be measured from a plasma sample.

About KineMed, Inc.

KineMed is a commercial-stage company focused on applying its proprietary biomarker platform technology to drug development, prescription and non-prescription medical diagnostics and the pairing of drugs with diagnostic biomarker tests.

KineMed’s diagnostic biomarker tests directly measure the biological processes that cause disease by revealing the flux, or rate of production and destruction, over a period of time, of the key molecules involved in these biological processes. KineMed believes that measuring molecular fluxes can provide interpretable information that may be predictive for clinically meaningful endpoints for a particular patient and are designed to reveal personalized information for a patient that can guide healthcare decisions. As a result, KineMed’s biomarkers have the potential to have a transformative effect on healthcare by providing information that can be used to make drug development more efficient, increase markets and sales for medicines and other health-related products and guide healthcare decisions by physicians and wellness decisions by consumers. Building on a legacy of collaborative relationships and experience performing biomarker tests in human disease research and drug development settings, KineMed is currently focused on commercializing biomarker tests in six areas: muscle biology, fibrotic diseases, neurodegenerative diseases, cardiometabolic diseases, skincare and cancer. KineMed’s muscle biology program represents its most advanced initiative that focuses its proprietary technology on a long-standing need in medicine and wellness management.

For more information about KineMed, please visit: www.kinemed.com